231 related articles for article (PubMed ID: 16407256)
1. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of CDK5/p25 binding by CDK inhibitors.
Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
5. Structure and regulation of the CDK5-p25(nck5a) complex.
Tarricone C; Dhavan R; Peng J; Areces LB; Tsai LH; Musacchio A
Mol Cell; 2001 Sep; 8(3):657-69. PubMed ID: 11583627
[TBL] [Abstract][Full Text] [Related]
6. Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2.
Chinami M; Yano Y; Yang X; Salahuddin S; Moriyama K; Shiroishi M; Turner H; Shirakawa T; Adra CN
J Biol Chem; 2005 Apr; 280(17):17235-42. PubMed ID: 15671017
[TBL] [Abstract][Full Text] [Related]
7. Identification of functional domains in the neuronal Cdk5 activator protein.
Poon RY; Lew J; Hunter T
J Biol Chem; 1997 Feb; 272(9):5703-8. PubMed ID: 9038181
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.
Zhang B; Tan VB; Lim KM; Tay TE
J Comput Aided Mol Des; 2006 Jun; 20(6):395-404. PubMed ID: 17054019
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
Lin H; Juang JL; Wang PS
J Biol Chem; 2004 Jul; 279(28):29302-7. PubMed ID: 15123618
[TBL] [Abstract][Full Text] [Related]
10. New structural insights into phosphorylation-free mechanism for full cyclin-dependent kinase (CDK)-cyclin activity and substrate recognition.
Zheng F; Quiocho FA
J Biol Chem; 2013 Oct; 288(42):30682-30692. PubMed ID: 24022486
[TBL] [Abstract][Full Text] [Related]
11. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death.
Hamdane M; Bretteville A; Sambo AV; Schindowski K; Bégard S; Delacourte A; Bertrand P; Buée L
J Cell Sci; 2005 Mar; 118(Pt 6):1291-8. PubMed ID: 15741232
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations.
Zhang B; Su ZC; Tay TE; Tan VB
J Mol Model; 2010 Jun; 16(6):1159-68. PubMed ID: 20013135
[TBL] [Abstract][Full Text] [Related]
13. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.
Chou KC; Watenpaugh KD; Heinrikson RL
Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524
[TBL] [Abstract][Full Text] [Related]
14. An in silico approach for the discovery of CDK5/p25 interaction inhibitors.
Zhang B; Corbel C; Guéritte F; Couturier C; Bach S; Tan VB
Biotechnol J; 2011 Jul; 6(7):871-81. PubMed ID: 21681969
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 5 phosphorylates endothelial nitric oxide synthase at serine 116.
Cho DH; Seo J; Park JH; Jo C; Choi YJ; Soh JW; Jo I
Hypertension; 2010 Feb; 55(2):345-52. PubMed ID: 20048197
[TBL] [Abstract][Full Text] [Related]
17. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.
Filgueira de Azevedo W; Gaspar RT; Canduri F; Camera JC; Freitas da Silveira NJ
Biochem Biophys Res Commun; 2002 Oct; 297(5):1154-8. PubMed ID: 12372407
[TBL] [Abstract][Full Text] [Related]
18. Structural Insights into Cdk5 activation by a neuronal Cdk5 activator.
Lim HY; Seow KT; Li Q; Kesuma D; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2001 Jul; 285(1):77-83. PubMed ID: 11437375
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
